{"disease":{"id":"cd19-positive","name":"cd19 positive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01865617","title":"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03233854","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03275493","title":"CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","has_results":false},{"nct_id":"NCT03512405","title":"Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03241940","title":"Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT05336409","title":"A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Century Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02529813","title":"CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04007029","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03523429","title":"PETHEMA-BLIN-01/PET069014 (BLIN-01)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT07491263","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT04029038","title":"Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03579927","title":"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}